Contact: Chad Rubin, Investor Relations Contact, The Trout Group LLC - 646.378.2947
DUSA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
WILMINGTON, MASS. – February 6, 2012 — DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 14th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria Hotel in New York on February 13-14, 2012. Mr. Doman is scheduled to present at 2:30 p.m. EST on February 14, 2012. Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately three hours following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform. Levulan® Kerastick® for topical solution plus DUSA’s BLU-U® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.